Over at Genetic Future, Daniel MacArthur is wondering what everyone wants to know: why buy Navigenics' Annual Insight service for $500 when you can have 23andMe's full genome scan for $100 cheaper? Navigenics recently announced an alternative to its $2,500 genetic testing service, the Annual Insight service, which costs $499 and analyzes genetic predisposition for ten common health conditions, including breast cancer, prostate cancer, colon cancer, and heart disease.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.